海外の治験の状況「1」での検索結果
2039件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Authorised
- Analysis of the antibody level against interferon beta before and after increase of dose in MS therapy - Interferon beta dose and antibody
- Multiple sclerosis
- Sweden
- 2005-03-21
Authorised
- Human pasteurized C1 esterase inhibitor concentrate (CE1145) in subjects with congenital C1-INH deficiency and acute abdominal or facial HAE attacks - C1-INH HAE study
- Hereditary angioedema (HAE) is characterized by congenital C1-INH deficiency. This is reflected by insufficient plasma concentrations of C1 – inhibitor or by synthesis of dysfunctional C1 – inhibitor molecules, which can lead to attacks of abdominal pain and/or severe swelling in the tissues e.g. of the face. Replacement with C1 esterase inhibitor concentrate is the treatment of choice of an acute attack of HAE. MedDRA version: 7.0 Level: LLT Classification code 10019860
- Bulgaria, Czech Republic, Hungary, Spain, Sweden, United Kingdom
- 2005-05-24
Authorised
- A randomised, double-blind, vehicle controlled, single centre, parallel group, comparative study of the efficacy of penciclovir 10 mg/g (1%) cream in preventing the appearance of classical lesions in recurrent cold sore sufferers. - Penciclovir 1% Cream Efficacy Study
- Cold Sores caused by the herpes simplex virus (HSV) type 1. MedDRA version: 9.1 Level: LLT Classification code 10049352 Term: Cold sores lip
- United Kingdom
- 2008-09-02
Authorised
- Anakinra (Kineret®) for a hereditary autoinflammatory disease with MEFV mutation and inflammasome activation.
- hereditary autoinflammatory disease with MEFV mutation and inflammasome activation;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
- Belgium
- 2015-12-03
Authorised
- Efficacy, Safety, and Tolerability of Fosmetpantotenate in patients with Pantothenate Kinase-associated Neurodegeneration (PKAN)
- Pantothenate kinase associated neurodegeneration (PKAN), an autosomal recessive genetic disorder, the most common form of Neurodegeneration with Brain Iron Accumulation (NBIA). It is a progressive, often fatal, neurodegenerative disease. MedDRA version: 19.1 Level: PT Classification code 10053643 Term: Neurodegenerative disorder System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Canada, Czech Republic, France, Germany, Italy, Norway, Spain, United Kingdom, United States
- 2017-03-30
Authorised
- Modulation of Clot Structure and Platelet Function by Aspirin in Individuals with Diabetes: the role of aspirin dose and Glycaemic control - Aspirin in Diabetes
- Type 1 Diabetes Mellitus
- United Kingdom
- 2009-07-06
Authorised
- The effects of subcutaneous insulin detemir on glucose flux, pharmacokinetics and brain function in type one diabetes - The effects of insulin detemir in type 1 diabetes
- Type 1 diabetes mellitus
- United Kingdom
- 2011-04-27
Authorised
- Effects of new longacting insulin analogs on metabolic control, endogenous insulin production, GH/IGF-I axis and quality of life – comparison of NPH, glargine och detemir insulin from the debut of T1DM in adolescents - Basal analog study
- Type 1 Diabetes Mellitus (T1DM)
- Sweden
- 2005-06-17
Authorised
- A randomised controlled study of continuous subcutaneous insulin infusion (CSII) therapy compared to conventional bolus insulin treatment in preschool aged children with Type 1 diabetes. - n/a
- Type 1 Diabetes Mellitus
- United Kingdom
- 2006-02-06
Authorised
- Comparison of the effect of insulin detemir and NPH insulin on dawn phenomenon in patients with Type 1 diabetes An open-labelled, randomised, cross-over, multi-center trial comparing the effect of insulin detemir versus NPH insulin as basal insulins on dawn phenomenon and the glycaemic control in patients with Type 1 diabetes treated on a basal-bolus regimen - Dawn phenomenon – insulin detemir
- Type 1 diabetes mellitus, dawn phenomenon
- Hungary
- 2006-01-25